Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Titel:
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Auteur:
Diéras, Véronique Miles, David Verma, Sunil Pegram, Mark Welslau, Manfred Baselga, José Krop, Ian E Blackwell, Kim Hoersch, Silke Xu, Jin Green, Marjorie Gianni, Luca